Welcome to our dedicated page for Silence Therapeutics plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silence Therapeutics plc filings document a foreign biotechnology issuer whose American Depositary Shares trade on Nasdaq under SLN, with each ADS representing three ordinary shares. The record includes 8-K reports furnishing quarterly and annual financial results, business highlights, Regulation FD presentations and other events tied to siRNA pipeline development.
The company’s disclosures also cover proxy materials for shareholder voting and governance, board composition, executive departures and appointments, committee changes, and the relationship between listed ADSs and ordinary shares. Clinical and business exhibits describe programs from the mRNAi GOLD platform, including SANRECO updates for divesiran in polycythemia vera and collaboration-related disclosures involving AstraZeneca.
Silence Therapeutics plc furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent business highlights. The press release is provided as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company’s American Depositary Shares trade on Nasdaq under SLN, with each ADS representing 3 ordinary shares of nominal value £0.05 per share.
Silence Therapeutics plc reported a clinical milestone under Other Events: it has completed enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV).
The company furnished a press release as Exhibit 99.1. The information, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
Silence Therapeutics plc reported that Michael Davidson resigned from its board of directors on August 11, 2025, stepping down immediately from the Board and from the Audit and Risk, Remuneration, and Science & Technology Committees. The company states that he left to focus on other time commitments, including his role as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and that his resignation was not due to any disagreement with the company, its management, or the Board.
After his departure, the Board reduced its size from five to four directors. The Board also appointed its chairman, Iain Ross, to the Audit and Risk Committee to fill the vacancy created by Dr. Davidson’s resignation, maintaining coverage of this key governance function.
Silence Therapeutics plc (SLN) – Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).
- 31 Jul 2025: 14,342 ADS at $6.18
- 1 Aug 2025: 4,034 ADS at $6.14
The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.
The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.
Silence Therapeutics plc (SLN) – Form 4 insider buying
10% owner Richard Ian Griffiths, via Cream Capital Ltd., disclosed open-market purchases on 21-22 Jul 2025 of 25,345 American Depositary Shares (ADS) at $6.04 and $6.09. Each ADS converts into three ordinary shares, increasing his indirect holding by roughly 76,035 ordinary shares.
Post-trade, Griffiths’ beneficial position totals ≈11.78 million ADS-equivalent shares. No sales were reported. Continued accumulation by a 10% holder generally signals confidence in the company’s outlook and may support sentiment toward SLN shares.